Generic Name and Formulations:
Glycopyrrolate 1mg; dye-free tabs.
Indications for ROBINUL:
Adjunct in peptic ulcer.
1–2mg 2–3 times daily; max 8mg daily.
Glaucoma. Unstable cardiovascular status. Asthma. GI or urinary tract obstruction. Paralytic ileus or intestinal atony. Toxic megacolon. Severe ulcerative colitis. Myasthenia gravis.
Reflux esophagitis. Autonomic neuropathy. Impaired hepatic or renal function. Cardiovascular disease. Tachycardia. Hypertension. Hyperthyroidism. High environmental temperature. Diarrhea. Elderly. Debilitated. Pregnancy (Cat.B). Nursing mothers.
Concomitant antacids may inhibit absorption. Cyclopropane anesthetics may cause arrhythmias. Additive anticholinergic effects with other anticholinergics, narcotic analgesics, type I antiarrhythmics, antihistamines, phenothiazines, tricyclics.
Anticholinergic effects (e.g., dry mouth, blurred vision, constipation).
Inj (vials) Single dose 1mL—25
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Effect of Infant Feeding Practices and Gut Microbiota on Overweight in First Year
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Cleared Blood Glucose Monitor Systems Not Always Accurate
- CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
- Vascular Mortality Declining in Adults With Diabetes in the United States